2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Myelodysplastic Syndromes
3
Hematologic Neoplasms
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Graft vs Host Disease
2
Stomatitis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
High Risk Myeloid Malignancies
1
Hematologic Diseases
1
HIV Infections
1
Carcinoma, Renal Cell
1
Burkitt Lymphoma
1
Interventions
pembrolizumab
157
Gemcitabine
140
Capecitabine
123
Paclitaxel
121
Fluorouracil
117
Oxaliplatin
110
Bevacizumab
106
Nivolumab
99
Docetaxel
98
Leucovorin
97
Cisplatin
90
Radiosurgery
88
Irinotecan
88
Carboplatin
86
Cyclophosphamide
72
Cetuximab
72
Magnetic Resonance Spectroscopy
68
Specimen Handling
60
Radiotherapy
60
Trastuzumab
59
Biopsy
59
Ipilimumab
53
Drug Therapy
51
Everolimus
48
Pemetrexed
46
Albumin-Bound Paclitaxel
45
130-nm albumin-bound paclitaxel
44
Doxorubicin
42
Fulvestrant
40
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Transplantation Conditioning
×
Clear all
NCT07627711
2026-06-04
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled
NCT07480928
2026-03-18
DUAL-NK-PDAC
Beijing Biotech
Phase 1/2
Recruiting
42 enrolled